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Abstract Clusterin is a ubiquitously expressed glycopro-
tein with multiple binding partners including IL-6, Ku70,
and Bax. Clusterin blocks apoptosis by binding to activated
Bax and sequestering it in the cytoplasm, thereby preventing
Bax from entering mitochondria, releasing cytochrome c,a n d
triggering apoptosis. Because increased clusterin expression
correlates with aggressive behavior in tumors, clusterin
inhibition might be beneficial in cancer treatment. Our
recent findings indicated that, in neuroblastoma cells,
cytoplasmic Bax also binds to Ku70; when Ku70 is
acetylated, Bax is released and can initiate cell death.
Therefore, increasing Ku70 acetylation, such as by using
histone deacetylase inhibitors, may be therapeutically useful
in promoting cell death in neuroblastoma tumors. Since
clusterin, Bax, and Ku70 form a complex, it seemed likely
that clusterin would mediate its anti-apoptotic effects by
inhibiting Ku70 acetylation and blocking Bax release. Our
results, however, demonstrate that while clusterin level
does indeed determine the sensitivity of neuroblastoma
cells to histone deacetylase inhibitor-induced cell death, it
does so without affecting histone deacetylase-inhibitor-
induced Ku70 acetylation. Our results suggest that in
neuroblastoma, clusterin exerts its anti-apoptotic effects
downstream of Ku70 acetylation, likely by directly blocking
Bax activation.
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Introduction
Despite its discovery more than 25 years ago in ram rete
testis fluid as the factor responsible for clustering of Sertoli
cells [1], the physiologic significance of clusterin (CLU)
expression in a range of other tissues is still unclear. CLU is
present in nearly all mammalian cells and in plasma, breast
milk, urine, and cerebrospinal fluid [2]. CLU expression
has been implicated as a factor in a variety of biological
processes such as spermatogenesis, lipid transport, cell
differentiation, cell death, and cell survival, which at least
partially accounts for the multiplicity of names given to this
protein, including ApoJ (apolipoprotein J) [3], TRPM-2
(testosterone-repressed prostatic message-2) [4], SGP-2
(sulfated glycoprotein 2) [5], XIP8 (ionizing radiation-
induced protein 8) [6], SP 40-40 (serum protein 40,40) [7],
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DOI 10.1007/s13277-010-0120-yCLI (complement-lysis inhibitor) [8], gp80, glycoprotein
III, and T64 [2, 9]. CLU is encoded by a single gene
located on human chromosome 8 [10]. There are two
isoforms that result from alternate translation start sites.
One is a glycosylated, secretable form that is translated
from the full-length CLU message using the first AUG
initiation codon. This isoform includes a leader sequence
directing ER synthesis and secretion as well as sites for
glycosylation. It is detected as two bands on immunoblots
that represent a 60-kDa uncleaved protein (p-CLU) and a
40-kDa product resulting from cleavage of the leader
sequence (m-CLU) [11]. The second isoform of CLU is
translated using the second AUG codon of the CLU
mRNA, and the product lacks a leader sequence, is not
secreted, and is not glycosylated. This form of CLU can be
detected in the nucleus (n-CLU) [12].
Increased CLU expression is related to neoplastic
progression in some cancers. The strongest evidence
linking high levels of CLU to carcinogenesis comes from
studies of breast and prostate cancer [13, 14]. Based in
part on differential expression levels between prostate
cancer and normal prostate tissue as well as on data
identifying CLU as an anti-apoptotic (pro-cell survival)
factor, clinical trials evaluating antisense RNA specific for
CLU (OGX-011) are underway in patients with prostate
cancer [15]. Tumor cell apoptosis is proposed as the
therapeutic mechanism for anti-CLU therapy. It is of
note, however, that depending on the tumor type studied,
CLU expression can have paradoxical anti-tumor effects
[16, 17].
CLU interacts with the pro-apoptotic multi-domain Bcl-2
family protein Bax and Bax–Ku70 protein complexes [18].
CLU–Bax binding inhibits Bax activation and mitochon-
drial translocation and cell death [19]. Recently, we showed
that histone deacetylase (HDAC) inhibitor (HDACI)-
induced cell death in neuroblastoma (NB) is Bax-
dependent and occurs as a result of HDACI-induced
disruption of Bax binding to Ku70 protein [20]. In NB,
HDACI treatment leads to increased Ku70 acetylation and,
because Ku70-Bax binding is acetylation sensitive, Bax is
released from Ku70, resulting in Bax-dependent apoptosis.
Since CLU is expressed in NB cells [17], its binding to Bax
and Ku70–Bax raises the possibility that CLU inhibits
apoptosis by modulating Ku70 acetylation. Here we test the
hypothesis that CLU suppresses Ku70 acetylation, stabiliz-
ing the Ku70–Bax complex and preventing apoptosis. We
conducted overexpression as well as CLU depletion experi-
ments to test this model. Although CLU prevents apoptosis
in NB, our results show that CLU does not affect Ku70
acetylation in NB cells. These results suggest that the anti-
apoptotic effects of CLU are independent of modulation of
Ku70 acetylation.
Materials and methods
Cell culture and cell transfection
Human neuroblastoma cell lines SH-EP1, SH-SY5Y,
IMR32, GOTO, SK-N-AS, and LA1-5S cultured in
modified Eagle’s medium (MEM) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin were maintained at 37°C in a humidified 5%
CO2 incubator. SH-SY5Y cells were transiently transfected
for viability assay with either pIRES-hyg Vector or pIRES-
sCLU or pIRES-nCLU using nucleofector kit V (Amexa) as
per the manufacturer’s protocol. SH-SY5Y cells expressing
transient or stable full-length CLU protein (f-CLU) or the
empty vector were generated by transfecting the cells with
vector or full-length CLU (f-CLU). Stable CLU expressing
clone was selected using 200 µg/ml of hygromycin.
Cell viability assay
N-type SH-SY5Y and S-type SH-EP1 human NB cell lines
as well as the SH-SY5Y cell lines expressing either stable
full-length CLU or empty vector were treated with varying
concentrations of Trichostatin A (TSA), and viability was
determined after 24 and 48 h by MTT assay as previously
described [20]. The viabilities of CLU-knocked down SH-
SY5Y and SH-EP1 cells were similarly measured. All
experiments were carried out in triplicate and the average
values and the standard deviations were calculated.
siRNA mediated silencing and quantitative real-time PCR
SH-SY5Y cells and SH-EP1 cells were plated at a density
of ∼2×10
6 cells per 10-cm plate 24 h before transfection.
The followingday,the cells weretransfectedeitherwithsmart
pool CLU siRNA or the scrambled non-targeting siRNA
(DharmaconInc.) usingnucleofectorkit V(Amexa) asperthe
manufacturer’s instruction. Mock transfection as well as the
non-targeting siRNA transfection served as controls. The
knockdown of CLU was confirmed 72 h after transfection by
immunoblot analysis using anti-CLU antibodies.
For quantitative real-time PCR analysis, total RNA was
prepared from SH-SY5Y and SH-EP1 cells. Samples were
then reverse transcribed and the levels of expression of
CLU gene before and after TSA treatment were quantified
using ABI prism 7700 sequence detector (Applied
Biosystems). CLU and the internal control 18S RNAs were
amplified using Taqman probes labeled with FAM from
Applied Biosystems. The standard curve for CLU and 18S
was prepared using serial dilution of known concentrations
of CLU cDNA (0.5, 2.5, 12.5, 62.5, 312.5, and 1562.5 pg).
From the Ct values, the quantity of CLU was calculated
286 Tumor Biol. (2011) 32:285–294after normalizing for the internal control 18S. For treatment
with TSA, fold activation was calculated using comparative
Ct method and untreated cells were kept as one and the fold
activation of the TSA treatment was then calculated at
8 and 16 h after treatment.
Immunoblot analysis and immunoprecipitation
For the immunoblot analysis, whole cell extracts were
prepared from SH-SY5Y, SH-EP1, IMR32, GOTO, SK-N-
AS, and LA1-5S human NB cell lines. In the case of NB
tumor, the samples were first homogenized in RIPA buffer
(50 mM Tris, pH 7.5; 150 mM NaCl; 1% NP-40; 1 mM
EGTA; 0.05% SDS) and then the extract was prepared. The
proteinswereseparatedby SDS–PAGE,transferredto PVDF
membrane, and then immunoblotted for CLU. The following
antibodies were used for western blot analyses: CLU (C-18)
and Ku70 (M-19) from Santa Cruz, and α-tubulin (T-4026)
from Sigma, and Bax NT (06-499) from Millipore. The
presence of protein was visualized by using Enhanced
Chemiluminescence Plus. Co-immunoprecipitation of en-
dogenous Bax before and after TSA treatment was per-
formed in CHAPS buffer according to the protocol described
by Sawada et al. [21].
Oligonucleotide microarray hybridization and analysis
Preparation of cDNA from total RNA, hybridization,
scanning, and image analysis were performed according to
the manufacturer’s protocol and as previously described
[22]. We used commercially available oligonucleotide
arrays (HG_U133A; Affymetrix, Santa Clara, CA, USA)
containing 22,283 probe sets. Each probe set typically
contains 11 perfectly matched 25-base long probes (PMs)
as well as 11 mismatched probes (MMs) that differ from the
PM probes at the central base. Using publicly available
software [23], we computed the average of the PM-MM
differences for each probe set on each array after discarding
the largest and smallest 20% of the PM-MM differences, and
scaled the data for each array to give a mean of 1,500 units.
The data was then quantile normalized to make the values of
99 evenly spaced quantities agree across all of the arrays. We
log-transformed values using log (max(x+50;0)+50). Con-
servative average fold differences were computed based on
the differences in log-transformed data.
Tissue microarray construction
Tissue specimens were obtained from the University of
Michigan Department of Pathology archives under the
approval of the Institutional Review Board. Tissue arrays
were constructed using three 1.0-mm cores taken from 48
paraffin-embedded, formalin-fixed neuroblastic tumors (32
NB, 10 intermixed and nodular ganglioneuroblastomas, and
six ganglioneuromas), five normal adrenal glands, and 20
other neural crest-derived (melanoma, pheochromocytoma)
and unrelated neoplasms (breast and colon adenocarcinoma,
Ewing sarcoma). The histologic classification of archived
tumor specimens was available, but all specimens were
blindly reviewed by a single pathologist (JAJ) and classified
according to current standards using the International Neuro-
blastoma Pathology Classification [24]. Core sampling was
performed to ensure optimal representation of both neuro-
blastic and stromal components were present. Completed
array blocks were cured at 37°C for at least 24 h, then heated
at 52°C for 15 min and rapidly cooled in an ice water bath.
Multiple 5-μm tissue sections were cut from each block with
every tenth section stained with hematoxylin/eosin for
morphologic assessment and comparison to adjacent immu-
nostained levels.
Protein expression analysis
Immunohistochemistry was performed using commercially
available monoclonal antibodies and standard manufac-
turers’ protocols on a Ventana automated stainer. Briefly,
slides were incubated with anti-CLU (C-18, Santa Cruz) at
a 1:1,000 dilution following a 20-min pretreatment in high
pH buffer at 95°C. Signals were evaluated for tumoral
distribution (neuroblastic cells versus Schwannian stromal
cells), cellular distribution (nuclear versus cytoplasmic), and
intensity (semiquantitatively graded as 0, 1+, 2+, or 3+). The
neuroblastic component was defined as any or all of the
following: neuroblasts, immature gangliocytoid cells, and
mature ganglion cells; the stromal component was defined as
spindled cells with scant clear to eosinophilic cytoplasm
embedded in a loose connective tissue matrix resembling
Schwann cells or perineurium. Specimens excluded from
analysis included those tumor array cores with insufficient
tissue or missingsections, those that were necrotic, and those
with insufficient neuroblastic or stromal components for
evaluation. For each evaluated specimen, the mean neuro-
blastic component staining and the mean stromal component
staining were calculated for all three cores.
Results
CLU mRNA expression in a panel of NB cell lines
identifies differential expression between N- and S-type cell
lines
NB tumors are composed of a mixed population of cells,
including neuroblastic (N-type) and stromal (S-type) cells
Tumor Biol. (2011) 32:285–294 287[24, 25]. Results in Fig. 1a show expression data on a subset
of genes that identify N-type versus S-type NB cells.
Vimentin, collagen type IV, and fibronectin, known stromal
markers [26], were expressed at significantly higher levels in
S-type cell lines, whereas neurofilament and chromogranin
A, markers of neuroblastic cells [27], were expressed at
higher levels in N-type cells. Analysis revealed marked
differences between N-type and S-type cells in their levels of
CLU messenger RNA; S-type cells expressed higher levels of
CLU RNA than N-type cell lines. These results suggest that
differences in CLU expression between N- and S-type cells in
culture may be responsible for biologic differences, such as
their differential sensitivity to treatment with HDACIs [28].
Cytoplasmic forms of CLU protein are expressed in NB
tumor tissue and NB cell lines
Basal CLU protein expression was evaluated in S-type and
N-type cell lines to determine if differential CLU protein
expression correlates with differential CLU mRNA expres-
sion and to define the isoforms expressed in NB cells. N-
type (GOTO, IMR32, and SH-SY5Y) and S-type (SH-EP1,
LA1-5S, and SK-N-AS) cells were analyzed by immuno-
blotting. To distinguish between different CLU forms, we
transfected SH-SY5Y cells with an expression vector
encoding Flag-tagged full-length CLU (f-Clu) that gener-
ates both p-CLU (precursor form) and m-CLU (mature
form) and a vector that encodes CLU starting at the second
ATG codon that results in n-CLU (n-CLU, Fig. 1b). With
these FLAG-epitope detected forms as standards, results
shown in Fig. 1c indicate that S-type NB cell lines express
much more of the p-CLU and m-CLU isoforms compared
to N-type cell lines where CLU protein expression is barely
detectable. Within each group of cells, p-CLU and m-CLU
are present in similar levels. n-CLU is not detected in any
of these cells. Thus, basal CLU protein expression differs
between culture phenotypes and correlates with differences
in RNA expression.
a.
b. c.
Fig. 1 CLU is differentially expressed in S-type NB cells. a
Expression of CLU and selected RNAs previously shown to be
specific for neuroblastic (top panel) or Schwannian/stromal cells
(bottom panel) in a panel of N-type [IMR-32, LA1-55n, SH-SY5Y,
SK-N-BE(2)-M17, and SH-IN (FSK-treated)] and S-type (SH-EP and
SMS-KCNs) NB cell lines as well as in three human NB tumor
specimens (NB1, NB2, and NB3). Color indicates fold difference of
each sample from the midpoint of the two means for S- and N-type
cells, with red indicating higher and green indicating lower expres-
sion. P values are from two-tailed t tests, and the fold difference
indicates the ratio of average N-type to S-type expression values. b
SH-SY5Y cells are transfected with a full-length CLU (f-Clu)
construct expressing precursor form (p-CLU) and mature form (m-
CLU) of CLU. Both forms are localized in the cytoplasm. Nuclear
form of CLU (n-CLU) is expressed from a CLU expression vector
starting at the second methionine of the CLU sequence. Note the
differences of the positions of each CLU on a SDS–polyacrylamide
gel. c Immunoblot analyses of three N-type (IMR32, SH-SY5Y, and
GOTO) and three S-type (SH-EP1, SK-N-AS, and LA1-5S) cell lines
show endogenous expression of secreted form of CLU and mature
form in S-type and not in N-type NB cell lines
288 Tumor Biol. (2011) 32:285–294To determine CLU protein expression in NB tumors,
tissue homogenates were prepared from tumor tissue and
immunoblotted to detect CLU. While the p-CLU is
c l e a r l yi d e n t i f i e di nf i v eo ft h en i n eN Bt u m o rs a m p l e s
(Fig. 2a), it is not clear whether these tumors contain the
nuclear form of CLU or the mature form of CLU (m-CLU)
or both. NB tumors are composed of histologically distinct
areas described as either neuroblastic rich regions or
Schwannian/stromal area. Given the in vitro differences
in expression between S-type and N-type cells, we
quantified CLU protein expression in NB tumors accord-
ing to neuroblastic or Schwannian/stromal region by
probing a NB tumor tissue microarray with anti-CLU
antibodies. This array contains tumor tissue representing
48 unique NB tumors (Fig. 2b). In apparent contrast to
results in NB cell lines, CLU protein expression is greater
in neuroblastic than in stromal tumor regions. Indeed, all
tumors had high (2+ or 3+) CLU expression in neuro-
blastic regions. CLU expression in Schwannian/stromal
regions was more variable; however, in the majority (29
out of 38), CLU stromal expression was low (0 or 1+
staining). Given this result, the same microarray was
probed for vimentin and S100, two other proteins whose
genes are differentially expressed in vitro with S-type
expression greater than N-type (see Fig. 1). For each,
expression in NB tumor tissue was nearly exclusive to
stromal regions (data not shown). Based on these results,
we conclude that cells comprising both neuroblastic and
Schwannian/stromal regions in NB tumors can express
CLU. Since CLU is expressed in cells from both tumor
regions, mechanistic experiments were designed to eval-
uate the function of CLU in both S- and N-type cells in
vitro.
HDACI treatment induces cytosolic CLU protein
expression
HDACIs increase acetylation of Ku70 protein. In NB cells,
this disrupts Ku70:Bax binding and releases activated Bax
to kill cells. Since CLU sequesters activated Bax, and binds
Ku70 and Bax:Ku70 protein complexes with unknown
effects on Ku70 acetylation, CLU expression may be a
factor limiting sensitivity of NB cells to HDACI therapy.
Since S-type cells in vitro are resistant to HDACI-induced
Ku70 acetylation, Bax activation, and cell death (whereas
N-type cells are responsive to this mechanism), finding
high levels of CLU protein in S-type cells provides support
for this hypothesis.
To test this, we first determined if HDACI treatment
affects CLU expression in three N-type NB cell lines
(GOTO, IMR32, and SH-SY5Y) and three S-type NB cell
lines (SH-EP1, LA1-5S, and SK-N-AS). In all N-type cells,
basal levels of CLU are low, but both the m and p forms are
clearly increased by TSA (1 μM, 24 h) treatment (Fig. 3a).
S-type cells have high basal CLU, and after TSA treatment
levels of the m and p forms are modestly increased (1.3 times
basal level). Even after maximal effects of TSA treatment are
accounted for (Fig. 3b), the overall protein level achieved in
GOTO and IMR32 cells in culture remains significantly
lower than the basal levels in all S-type cells. However, the
CLU expression in SH-SY5Y cells is high after TSA
treatment compared to that of the S-type cells. In parallel
with the increase in CLU protein, TSA treatment induces a
corresponding increase in CLU mRNA levels in N-type
cells. RT–P C R - q u a n t i f i e dC L Um R N Aa f t e rT S At r e a t m e n t
showed increased mRNA levels in SH-SY5Y cells 8
and 16 h after TSA treatment (Fig. 3c). CLU message level
b. a.
Fig. 2 Clusterin is highly expressed in the neuroblastic, but not
stromal, components of neuroblastic tumors. a The NB tissue is
obtained from our tissue core at the University of Michigan, with one
stage I, four stage II, one stage III, and three stage IV tumors. b
Immunohistochemistry was performed with antibodies specific for
CLU as described in the text. Strong cytoplasmic staining is seen in
the small neuroblasts of a poorly differentiated NB (left) and the
larger, more mature-appearing ganglion cells of an intermixed
ganglioneuroblastoma (right). Staining prevalence and intensity were
scored semiquantitatively from 0 to 3+, with separate scores assigned
to the histologically distinct neuroblastic and stromal cells. Categori-
zation of expression revealed that whereas the N-type components of
all but one tumor had at least 2+ expression (mean 2.95), most S-type
components had CLU present at less than 1+ levels (mean 0.95)
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response to TSA treatment. We also tested two other
HDAC inhibitors, SAHA and MS-275, which also
indicated increased CLU level in SH-SY5Y cells, but to
a lesser extent in SH-EP1 cells (Fig. 3d). Taken together,
these results mean that in addition to basal CLU
expression, HDACI-induced CLU expression may be a
factor modulating the effectiveness of this class of drugs
against NB.
We tested whether increased CLU expression occurs
when NB cells are exposed to other cytotoxic treatments.
SH-SY5Y and SH-EP1 were treated with doxorubicin, VP-
16, cisplatin, or irradiation (15 Gy). CLU expression was
not increased with any of the other treatments (Fig. 4),
suggesting that in NB cells, CLU expression is selectively
increased by HDACIs.
CLU limits HDACI-induced cell death without inhibiting
HDACI-induced Ku70 acetylation
TodeterminewhetherbasalCLUexpressionaffectssensitivity
of HDACIs, various amounts of a vector expressing full-
length CLU cDNA (f-CLU) expression vector were trans-
fected into SH-SY5Y cells. In the transfected cells, basal
levels of p-CLU and m-CLU are increased (data not shown).
While TSA reduces the viability of the NB cells in a dose-
dependent manner, increasing amounts of transfected CLU
reduces the sensitivity to TSA (Fig. 5a). Since CLU is known
to interact with activated Bax, we tested whether expression
of CLU will block Bax entering into the mitochondria.
Results shown in Fig. 5b indeed demonstrate that stable
expression of CLU in SH-SY5Y reduces the appearance of
Bax in mitochondria after TSA treatment.
a.
b.
c. d.
Fig. 3 Clusterin expression is increased with HDACI treatment. a NB
N-type (IMR32, SH-SY5Y, and GOTO) and S-type (SH-EP1, SK-N-
AS, and LA1-5S) cell lines were treated with 1 μM TSA for 24 h
before immunoblotting with anti-CLU antibody. β-Tubulin was used
as a loading control. b SH-SY5Y and SH-EP1 cell lines were treated
with 1 μM TSA and cell lysates were collected at different time points
(4, 8,16, 20, and 24 h), and the expression of CLU was analyzed by
immunoblotting. c mRNA level CLU is present in S-type SHEP1 cells
whereas it is induced after 1 μM TSA treatment in N-type SH-SY5Y
cells both after 16 and 24 h. d SH-SY5Y cells and SH-EP1 cell lines
were treated with 1 μM of TSA, SAHA, or MS-275 for 24 h, and the
expression of CLU was analyzed by immunoblotting
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has on sensitivity to TSA-induced cell death. We knocked
down SH-SY5Y cells and SH-EP1 cells with CLU-specific
siRNA. As shown in Fig. 5c, CLU siRNA successfully
prevented the TSA-induced increased CLU level in SH-
SY5Y cells and reduced basal levels of CLU in SH-EP1
cells. Indeed, knocking down CLU in both SH-SY5Y and
SH-EP1 cells sensitized TSA-induced killing (Fig. 5d).
Since CLU binds to both activated Bax [19] and also to
Ku70:Bax complexes [18], we envisioned two alternative
mechanisms by which CLU can modulate the therapeutic
response to HDACIs, either by maintaining Ku70:Bax
binding or sequestering activated Bax. To distinguish
between these models, we evaluated binding between
Ku70 and Bax before and after HDACI treatment.
Figure 6a shows that in SH-SY5Y cells, with low levels
a. b.
Fig. 4 CLU is induced by
HDACI but not by other
stressors in NB cells. Both
N-type SH-SY5Y (a) and S-type
SH-EP1 (b) cell lines were
treated for 24 h with TSA
(1 μM), cisplatin (10 μg/ml),
doxorubicin (Dox) (0.5 μg/ml),
etopicide (VP16) (10 μg/ml), or
radiation (15 Gy for 1 or 17 h as
indicated). The presence of CLU
was analyzed by immunoblot
using CLU-specific antibodies
a.
b.
c.
d.
Fig. 5 Knocking down CLU sensitizes NB cells to TSA-induced cell
death. a Various amounts of CLU expression vectors (as indicated)
were transfected into SH-SY5Y cells. The cells were treated with
different concentration of TSA for 24 h as shown. Cell viability is
determined by MTT assay. Results are expressed as the percentage of
viable cells compared with vehicle-treated controls (mean ± SD; n=3).
b Stable SH-SY5Y cell line expressing full-length CLU or vector were
treated with TSA (1 μM) for 0, 4, 8, and 16 h as indicated.
Mitochondria were isolated; Bax level was determined by immuno-
blotting. VDCA1 is used as the loading control for mitochondria
fraction. c SH-SY5Y cells or SH-EP1 cells were transfected with
scrambled siRNA or CLU-specific siRNA. Forty-eight hours after
transfection, cells were treated with TSA (1 μM, 24 h). Cells in mock
sample received no transfection. Immunoblot shows effective knock-
down of CLU. d SH-SY5Y cells or SH-EP1 cells were transfected with
CLU-specific siRNA as shown in (c). The cells were treated with
varying concentrations of TSA for 24 h as shown. Cell viability was
determined by MTT assay. Results are expressed as the percentage of
viable cells compared with vehicle-treated controls (mean ± SD; n=3)
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However, after HDACI treatment, the level of Ku70
binding to Bax decreases, as shown previously [20, 28].
Interestingly, CLU overexpression does not alter binding
between Ku70 and Bax before or after TSA treatment
(Fig. 6a). Furthermore, TSA treatment only slightly reduces
the binding between CLU and Ku70 (Fig. 6b).
Since CLU does not prevent HDACI-induced disruption
of Ku70:Bax complexes, we predicted that it does not affect
Ku70 acetylation in response to TSA. To test this,
acetylated proteins were immunoprecipitated from cyto-
plasmic extracts prepared from SH-SY5Y cells transfected
with f-CLU that were either HDACI treated or untreated.
Acetylated proteins were resolved on SDS–PAGE and
immunoblotted with Ku70-specific antibody. As shown in
Fig. 6c, CLU expression did not reduce levels of acetylated
Ku70. In an orthogonal approach, we used CLU-specific
siRNA transfection to knock down CLU in SH-SY5Y cells
(Fig. 6d). When Ku70 acetylation was determined in cells
treated with TSA, no differences were detected between
CLU knockdown and control cells.
Discussion
HDACIs have the potential to be an effective therapy for
NB. Since these agents are not broadly cytotoxic but
instead act selectively against particular cell types, under-
standing key elements of the mechanism(s) by which they
kill tumor cells is critical to apply these drugs against
tumors that are most likely to respond. At present, it is not
known whether all NB tumors or which particular subset
of NB tumors are likely to be responsive to HDACI
therapy. The results from this study showing that CLU
protein expression limits HDACI-induced NB tumor cell
apoptosis identify CLU as a molecular marker associated
with resistance to HDACIs and present an opportunity to
combine therapeutic approaches designed to decrease
CLU expression together with HDACI-based treatment to
more effectively treat NB tumors. Our results support a
model in which CLU functions as an anti-apoptotic
factor in NB cells. We have shown that the anti-apoptotic
forms of CLU (p-CLU and m-CLU) are exclusively
expressed in NB cell lines, but in NB tumors, it is not
a.
b.
c.
d.
Fig. 6 CLU does not affect Ku70 acetylation or Ku70–Bax binding in
NB cells. a Stable SH-SY5Y cell line expressing full-length CLU or
vector were treated with TSA (1 μM, 24 h) and cytoplasmic extracts
were immunoprecipitated using Bax-specific antibodies or normal
rabbit serum (NRS) as control. The immunoprecipitates were separated
by SDS–PAGE and probed with Ku70, CLU, or Bax antibodies. b
SH-SY5Y cells were treated with vehicle or TSA (1 μM, 24 h). CLU
was immunoprecipitated using CLU-specific antibodies or normal
mouse serum (NMS). The immunoprecipitates were separated by
SDS–PAGE and probed with Ku70 or CLU antibodies. c Stable SH-
SY5Y cells expressing full-length CLU or vector were treated with
TSA (1 μM, 24 h). Cytoplasmic extracts were immunoprecipitated
using an anti-acetyl-lysine antibody (K103). The immunoblot was
probed with Ku70 as shown. d CLU siRNA or scramble siRNA-
treated SH-SY5Y cells were treated with TSA (1 μM, 24 h).
Cytoplasmic extracts were immunoprecipitated using anti-acetyl-
lysine antibody (K103). The immunoblot was probed with Ku70
antibody
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expressed. While there is a differential expression of
basal CLU in NB cells (high in S-type but low in N-type
NB cells), inhibiting HDACs induces expression of CLU
in N-type, but only a modest increase is observed in S-
type NB cells. This increase of CLU expression reduces
Bax-mediated cell death as overexpression of CLU
reduces HDACI-induced cell death activity, whereas
knocking down CLU in NB cells facilitates HDAC-
induced cell death.
We have previously shown that NB tumor cells are
variably sensitive to HDACIs. Specifically, S-type cells are
resistant whereas N-type cells are sensitive [20, 28]. In
sensitive N-type cells, HDACI treatment increases Ku70
protein acetylation at two lysine residues, 539 and 542.
These residues regulate Ku70 binding to Bax, a potent
inducer of apoptosis. Acetylation at these sites is necessary
for HDACI-induced NB cell death. Mechanistically, HDAC
inhibition increases Ku70 acetylation disrupting Ku70:Bax
binding which in turn leads to Bax activation and Bax-
dependent cell death.
Since CLU expression is significantly higher in HDACI-
resistant S-type NB cell lines compared to sensitive N-type
lines, and that CLU protein binds Ku70, Bax, and Ku70:
Bax complexes, the significance of CLU expression in
terms of regulating Ku70 acetylation was investigated. We
initially reasoned that since CLU is proposed to be anti-
apoptotic in NB cells, and that CLU is shown to interact
with Ku70 and Bax in cells, one potential model would be
that CLU suppressed Bax-dependent cell death by binding
to Ku70 and inhibiting HDACI-induced Ku70 acetylation.
However, our results do not support this model. Our results
showed that CLU interacts with Ku70 at basal level in N-
type NB cells. TSA treatment increases the binding
between CLU and Bax but reduces the binding between
Ku70 and CLU. Overexpression of CLU does not alter this
pattern, suggesting that CLU level increase, either by TSA
or by overexpression, does not affect CLU and Ku70
binding. Furthermore, we have shown that while TSA
treatment induces Ku70 acetylation in N-type NB cells,
CLU overexpression or CLU depletion by siRNA did not
affect the TSA-induced increase of Ku70 acetylation.
These results suggest that the anti-apoptotic effect of
CLU in TSA-induced NB cell death occurs downstream
of Ku70 acetylation, perhaps, as described previously, by
CLU binding to activated Bax, reducing Bax-dependent
activation.
Collectively, our results indicate that high level of CLU
in NB cells will serve as a biomarker to predict resistance
of drugs that induce Bax activation. Because HDACIs are
generally non-toxic to other cells, targeting CLU in NB
cells can be used as a strategy to increase NB sensitivity to
HDACIs.
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